After several trials, the FDA approved the first GLP-1 medication for weight loss in 2021, branded as Wegovy. Dr. Shweta Akhouri is a board-certified family and obesity medicine physician.

“I would speculate that [the surge of prescriptions for women] would have been because of weight loss or obesity,” says Lee. “There is a societal bias or extra burden that women take upon ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

CLIFTON PARK, N.Y. — As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching peak obesity. Jessica Riggins ...

Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection. If Eli Lilly has its way, this may be the future of obesity care.

There were 125 adults with overweight or obesity enrolled in a five-part trial. The trial’s primary endpoint was treatment-emergent adverse events. Weight loss with amycretin was compared with ...

(Allison Robbert/The Washington Post) The Trump administration has promised that addressing childhood obesity will be a ... have shown much promise for weight loss, they remain prohibitively ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...

A doctor may also prescribe it off-label for weight loss. Doctors usually prescribe Ozempic to people with type 2 diabetes. However, a person with obesity may receive it off-label if weight loss ...

The first shot shows Lizzo in a mirror selfie, while the second zooms in on her midsection with her weight loss stats included ... appearing in Men’s Health, Women’s Health, Self, Glamour ...

a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s. Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher ...